tweetindex
ID

Agemica ✓

@AgemicaCom

more life

1 247Followers
2Following
14Posts total
1.2MViews on collected posts

Postingan terbaru

@AgemicaCom Please no, we need boomers to die. 3.6K views · 141 likes · 1 reposts · 2 replies Open on X →
You deserve more than 80 years of life. We're here to bring this life to you. https://t.co/RSmihefW9J 8.2K views · 27 likes · 2 reposts · 1 replies Open on X →
Dr. Jayakumar Rajadas. Scientific advisor. Three decades developing drugs. 260+ publications. 82+ patents. Founded Stanford’s Advanced Drug Delivery and Regenerative Biomaterials Laboratory. Bringing the experience needed to help discoveries become medicines. https://t.co/xYO
8.9K views · 28 likes · 1 reposts · 1 replies Open on X →
Prof. Michael Snyder. Scientific advisor. Led Stanford’s Department of Genetics for 15 years. Pioneer in genomics, proteomics and personal multi-omics. Now advising Agemica’s work on the biology of aging. https://t.co/IDPtyUvZfl
10K views · 26 likes · 1 reposts · 2 replies Open on X →
Dr. Yasaman Kalantar-Motamedi. Co-founder. Cambridge PhD. UCL MSc in machine learning. 12 years in AI drug discovery and vaccine design. Building the connection between what a machine predicts and what biology proves. https://t.co/9VKAWo1LsA
10.6K views · 31 likes · 1 reposts · 1 replies Open on X →
We are led by a concentrated team of highly experienced AI researchers and drug discovery veterans including: @RonjonNag (founder) - Cambridge PhD. MIT MS. Stanford professor of genetics, who founded companies acquired by Apple, BlackBerry and Motorola. Now bringing that https:
13.6K views · 45 likes · 2 reposts · 1 replies Open on X →
Drugs treat cancer once it's there. A vaccine can stop it before it starts. That's the other half of what we're building. Personalized cancer vaccines already work, Moderna cut melanoma recurrence by 49%. But they cost $100,000–$300,000 per patient, take 4–7 weeks to make, and 15.6K views · 58 likes · 1 reposts · 2 replies Open on X →
Agemicas mission is to accelerate drug discovery through frontier AI and to help all of humanity reach a healthy lifespan of 150 years. We've started with tackling cancer. Cancer is taking 9.8 million deaths every year - approximately 27,000 every day. We believe this doesn't h
25.7K views · 191 likes · 7 reposts · 9 replies Open on X →
Introducing Agemica. On our mission to solve aging. https://t.co/eAZcNuIZGn
1:52
1.1M views · 1.4K likes · 115 reposts · 107 replies Open on X →

Dibandingkan akun berukuran sama

9 postingan dari 90 hari terakhir, dibandingkan dengan rentang under 10K pengikut. tampil luas, tetapi sedikit penonton yang merespons.

Median tayangan10 614akun ini4 175median untuk under 10K
Jangkauan, %851.16%akun ini250.82%median untuk under 10K
Interaksi, %0.35%akun ini1.41%median untuk under 10K
MetrikAkun iniMedian untuk under 10KRasio
Median tayangan per postingan10 6144 1752.54×
Jangkauan (tayangan ÷ pengikut)8.5× audience2.5× audience3.39×
Tingkat interaksi0.35%1.41%0.25×

Akun lain pada rentang ini →   Bandingkan dengan akun lain →   Bagaimana tolok ukur ini disusun →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

1.1M21 Sep
25.7K
15.6K
13.6K
10.6K
10K
8.9K
8.2K
3.6K22 Sep

Last 9 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.17%21 Sep
0.81%
0.39%
0.35%
0.31%
0.30%
0.34%
0.38%
4.02%22 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for under 10K accounts is 1.41%.

What the audience does

Likes61.4%1 993 in total
Reposts4.0%131 in total
Replies3.9%126 in total
Quotes6.0%196 in total
Bookmarks24.6%800 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Akun serupa